Litigation Details for Allergan USA, Inc. v. Aurobindo Pharma Limited (D. Del. 2019)
✉ Email this page to a colleague
Allergan USA, Inc. v. Aurobindo Pharma Limited (D. Del. 2019)
| Docket | ⤷ Sign Up | Date Filed | 2019-12-20 |
| Court | District Court, D. Delaware | Date Terminated | 2022-06-01 |
| Cause | 35:271 Patent Infringement | Assigned To | Richard Gibson Andrews |
| Jury Demand | None | Referred To | |
| Parties | ALLERGAN USA, INC. | ||
| Patents | 7,737,142; 7,943,621; RE47,350 | ||
| Attorneys | Christopher B. Ferenc | ||
| Firms | Kratz & Barry LLP | ||
| Link to Docket | External link to docket | ||
Small Molecule Drugs cited in Allergan USA, Inc. v. Aurobindo Pharma Limited
The small molecule drug covered by the patents cited in this case is ⤷ Sign Up .
Details for Allergan USA, Inc. v. Aurobindo Pharma Limited (D. Del. 2019)
| Date Filed | Document No. | Description | Snippet | Link To Document |
|---|---|---|---|---|
| 0000-00-00 | External link to document | |||
| 2019-12-19 | 1 | Complaint | United States Patent Nos. 7,737,142 (“the ’142 Patent”) and 7,943,621 (“the ’621 Patent”) (collectively…has listed the asserted patents and U.S. Patent No. RE47,350 (“the ’350 Patent”) in the Approved Drug … 1. This action for patent infringement, brought pursuant to the patent laws of the United States…28. This civil action for patent infringement arises under the patent laws of the United States, including… copy of the ’142 Patent is attached as Exhibit A. 61. The ’621 Patent, titled “Salts of | External link to document |
| 2021-06-02 | 104 | Patent/Trademark Report to Commissioner of Patents | the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) RE47,350 E . (Dorsney, Kenneth… 2019 1 June 2022 1:19-cv-02317 835 Patent - Abbreviated New Drug Application(ANDA) None | External link to document |
| 2021-08-25 | 140 | Stipulation to EXTEND Time | asserted patents, including U.S. Patent Nos. 7,737,142 (the '142 Patent) and 7,943,621 (the '621 Patent) and…Scheduling Order, for all asserted patents, including the '142 and '621 Patents to September 15, 2021 and September… 2019 1 June 2022 1:19-cv-02317 835 Patent - Abbreviated New Drug Application(ANDA) None | External link to document |
| 2021-12-21 | 226 | Notice of Service | Infringement Contentions to Zydus for U.S. Patent Nos. 7,737,142; 7,943,621; and 8,765,765, (2) Plaintiffs…Infringement Contentions to Aurobindo for U.S. Patent Nos. 7,737,142; 7,943,621; and 8,765,765, and (3) Plaintiffs…Infringement Contentions to Sun for U.S. Patent Nos. 7,737,142; 7,943,621; 8,569,497; and 8,765,765 - filed… 2019 1 June 2022 1:19-cv-02317 835 Patent - Abbreviated New Drug Application(ANDA) None | External link to document |
| 2022-01-30 | 237 | Notice of Service | Infringement of Claims 24 and 25 of U.S. Patent No. 7,737,142 by Aurobindo Pharma Limited and Aurobindo…Infringement of the Asserted Claims of U.S. Patent No. 7,737,142 by Aurobindo Pharma Limited and Aurobindo…Non-Obviousness Supporting the Validity of U.S. Patent No. 7,737,142; (6) Opening Expert Report of Dr. Gregory…-Obviousness Supporting Validity of U.S. Patent No. 7,737,142; (7) Opening Expert Report of Dr. Christopher…Regarding Infringement Claims 24 and 25 of U.S. Patent No. 7,737,142 by Sun Pharmaceuticals Industries Limited | External link to document |
| 2020-04-21 | 24 | Patent/Trademark Report to Commissioner of Patents | the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) RE47,350 . (Farnan, Kelly) (… 2019 1 June 2022 1:19-cv-02317 835 Patent - Abbreviated New Drug Application(ANDA) None | External link to document |
| >Date Filed | >Document No. | >Description | >Snippet | >Link To Document |
